Molecular Biomarker Expression in Window of Opportunity Studies for Oestrogen Receptor Positive Breast Cancer—A Systematic Review of the Literature

Francis, James W.M.; Saundh, Manmeet; Parks, Ruth M.; Cheung, Kwok Leung

Abstract

Window of opportunity (WoO) trials create the opportunity to demonstrate pharmacodynamic parameters of a drug in vivo and have increasing use in breast cancer research. Most breast cancer tumours are oestrogen receptor-positive (ER+), leading to the development of multiple treatment options tailored towards this particular tumour subtype. The aim of this literature review is to review WoO trials pertaining to the pharmacodynamic activity of drugs available for use in ER+ breast cancer in order to help guide treatment for patients receiving neoadjuvant and primary endocrine therapy. Five databases (EMBASE, Cochrane, MEDLINE, PubMed, Web of Science) were searched for eligible studies. Studies performed in treatment-naïve patients with histologically confirmed ER+ breast cancer were included if they acquired pre- and post-treatment biopsies, compared measurement of a proteomic biomarker between these two biopsies and delivered treatment for a maximum mean duration of 31 days. Fifteen studies were eligible for inclusion and covered six different drug classes: three endocrine therapies (ETs) including aromatase inhibitors (AIs), selective oestrogen receptor modulators (SERMs), selective oestrogen receptor degraders (SERDs) and three non-ETs including mTOR inhibitors, AKT inhibitors and synthetic oestrogens. Ki67 was the most frequently measured marker, appearing in all studies. Progesterone receptor (PR) and ER were the next most frequently measured markers, appearing five and four studies, respectively. All three of these markers were significantly downregulated in both AIs and SERDs; Ki67 alone was downregulated in SERMs. Less commonly assessed markers including pS6, pGSH3B, FSH and IGF1 were downregulated while CD34, pAKT and SHBG were significantly upregulated. There were no significant changes in the other biomarkers measured such as phosphate and tensin homolog (PTEN), Bax and Bcl-2.WoO studies have been widely utilised within the ER+ breast cancer subtype, demonstrating their worth in pharmacodynamic research. However, research remains focused upon routinely measured biomarkers such ER PR and Ki67, with an array of less common markers sporadically used.

Citation

Francis, J. W., Saundh, M., Parks, R. M., & Cheung, K. L. (2022). Molecular Biomarker Expression in Window of Opportunity Studies for Oestrogen Receptor Positive Breast Cancer—A Systematic Review of the Literature. Cancers, 14(20), Article 5027. https://doi.org/10.3390/cancers14205027

• Journal Article Type: Article
• Acceptance Date: Oct 11, 2022
• Online Publication Date: Oct 14, 2022
• Publication Date: Oct 1, 2022
• Deposit Date: Nov 7, 2022
• Publicly Available Date: Nov 7, 2022
• Journal: Cancers
• Electronic ISSN: 2072-6694
• Publisher: MDPI AG
• Peer Reviewed: Peer Reviewed
• Volume: 14
• Issue: 20
• Article Number: 5027
• DOI: https://doi.org/10.3390/cancers14205027
• Keywords: breast cancer; window of opportunity; oestrogen receptor-positive
• Public URL: https://nottingham-repository.worktribe.com/output/12624623
• Publisher URL: https://www.mdpi.com/2072-6694/14/20/5027